EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

The effect of Biktarvy (B/F/ TAF ) on whole‐body insulin sensitivity, lipid and endocrine profile in healthy volunteers

Joseph Heskin iD, Roya Movahedi iD, Sujin Kang iD, Ruth Byrne, Krestine Elecito, Perrine Gridel, Paola Marchesani, Graeme Moyle, Ana Milinkovic, Marta Boffito iD

HIV Medicine · 2026

DOI: 10.1111/hiv.70208 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift HIV Medicine, 2026. Verfasst von Joseph Heskin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Chelsea and Westminster NHS Foundation Trust, London, UK. Hauptthemen laut MEDLINE: Insulin Resistance, Adenine, Anti-HIV Agents. Die Arbeit nennt 13 Literaturangaben. Gefördert von: Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Biktarvy is a single‐tablet anti‐retroviral regimen composed of a second‐generation integrase‐inhibitor (Bictegravir), in combination with tenofovir alafenamide and emtricitabine. Biktarvy has been shown to be highly effective in achieving and sustaining viral suppression. However, several studies have highlighted altered glycaemic control in individuals switching to Biktarvy from other regimens. The aim of this study was to quantify glucose disposal rates (GDR) in HIV‐seronegative healthy volunteers following the administration of Biktarvy.

Method

A 72 day, open‐label, two‐arm, crossover, single‐centre study. Participants were randomized 1:1 to either start 28 days of Biktarvy followed by 44 days without treatment (Group 1), or no treatment for 43 days followed by Biktarvy treatment for 28 days (Group 2). A hyper‐insulinaemic‐euglycaemic clamp was carried out at days 1, 28 and 72 with a 14‐day washout period following the second clamp. Statistical assessments of change in estimated GDR were carried out using Wilcoxon signed‐rank test (within‐group) and Two‐sample Wilcoxon rank‐sum (Mann–Whitney) test (between‐group). The primary study outcome was change from baseline in total body glucose disposal by euglycaemic clamp method following 28 days treatment.

Results

A total of 18 volunteers completed the study, with 11 in group 1 and seven in group 2. Within Group 1 the mean GDR was 7.52 mg/kg/min (SD 3.67) at baseline versus 8.50 mg/kg/min (SD 3.72) at day 28 ( p = 0.32) and a mean percentage change of −13% (0.98). Within Group 2, the mean GDR was 6.54 mg/kg/min (SD 1.86) on day 28 versus 5.85 mg/kg/min (2.67) on day 72 ( p ‐value = 0.38) mean percentage change −11% (−0.69). There was no statistically significant change between the groups at baseline (Mean 7.52 [SD 3.67] vs Mean 6.11 [SD 2.94], p ‐value = 0.31), at Day 28 (Mean 8.50 [SD 3.72] vs Mean 6.54 [SD 1.86], p ‐value = 0.27), or at Day 72 (Mean 9.65 [SD 5.07] vs Mean 5.85 [SD 2.67], p ‐value = 0.13). GDR on the final day of administration of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) was not significantly different ( p = 0.104) between Group 1 Day 28 (6.64 [interquartile range (IQR) 5.83, 10.59] mg/kg/min) and Group 2 day 72 (0.28 [IQR 3.99, 8.79] mg/kg/min).

Conclusion

Treatment with Biktarvy for 28 days was not associated with a statistically significant impact on total body insulin sensitivity as measured using a hyper‐insulinaemic‐euglycaemic clamp method. However, long‐term data on the metabolic effects of Biktarvy are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Insulin ResistanceAdenineAnti-HIV AgentsHumansMaleAdultCross-Over StudiesFemaleBlood GlucoseYoung AdultGlucose Clamp TechniqueHealthy VolunteersMiddle AgedTenofovir

Stichwörter der Autor:innen

BiktarvyHIVinsulin‐sensitivitymetabolic

Substanzen

Blood GlucoseAdenineAnti-HIV AgentsTenofovir

Autor:innen und Institutionen

  • Chelsea and Westminster NHS Foundation Trust, London, UK.
  • Imperial College London, London, UK.

ORCID-Profile: Joseph Heskin, Roya Movahedi, Sujin Kang, Marta Boffito

Förderung

  • Gilead Sciences

Zitieren

APA

Heskin, J., Movahedi, R., Kang, S., Byrne, R., Elecito, K., Gridel, P., Marchesani, P., Moyle, G., Milinkovic, A., & Boffito, M. (2026). The effect of Biktarvy (B/F/ TAF ) on whole‐body insulin sensitivity, lipid and endocrine profile in healthy volunteers. HIV Medicine. https://doi.org/10.1111/hiv.70208

Vancouver

Heskin J, Movahedi R, Kang S, Byrne R, Elecito K, Gridel P, et al. The effect of Biktarvy (B/F/ TAF ) on whole‐body insulin sensitivity, lipid and endocrine profile in healthy volunteers. HIV Medicine. 2026. doi:10.1111/hiv.70208

BibTeX
@article{Heskin2026,
  author = {Heskin, Joseph and Movahedi, Roya and Kang, Sujin and Byrne, Ruth and Elecito, Krestine and Gridel, Perrine and Marchesani, Paola and Moyle, Graeme and Milinkovic, Ana and Boffito, Marta},
  title = {The effect of Biktarvy (B/F/ TAF ) on whole‐body insulin sensitivity, lipid and endocrine profile in healthy volunteers},
  journal = {HIV Medicine},
  year = {2026},
  doi = {10.1111/hiv.70208}
}
Kostenlos starten →